title: Chronic fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke.
abstract: Cognitive deficits, including spatial memory impairment, are very common after ischemic stroke. Neurogenesis in the dentate gyrus (DG) contributes to forming spatial memory in the ischemic brain. Fluoxetine, a selective serotonin reuptake inhibitor, can enhance neurogenesis in the hippocampus in physiological situations and some neurological diseases. However, whether it has effects on ischemia-induced spatial cognitive impairment and hippocampal neurogenesis has not been determined. Here we report that fluoxetine treatment (10 mg kg(-1), i.p.) for 4 weeks promoted the survival of newborn cells in the ischemic hippocampus and, consequently, attenuated spatial memory impairment of mice after focal cerebral ischemia. Disrupting hippocampal neurogenesis blocked the beneficial effect of fluoxetine on ischemia-induced spatial cognitive impairment. These results suggest that chronic fluoxetine treatment benefits spatial cognitive function recovery following ischemic insult, and the improved cognitive function is associated with enhanced newborn cell survival in the hippocampus. Our results raise the possibility that fluoxetine can be used as a drug to treat poststroke spatial cognitive deficits.
authors: Department of Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, China.
authors: Wen-Lei
authors: WL
authors: Li
authors: Hui-Hui
authors: HH
authors: Cai
authors: Bin
authors: B
authors: Wang
authors: Ling
authors: L
authors: Chen
authors: Qi-Gang
authors: QG
authors: Zhou
authors: Chun-Xia
authors: CX
authors: Luo
authors: Na
authors: N
authors: Liu
authors: Xin-Sheng
authors: XS
authors: Ding
authors: Dong-Ya
authors: DY
authors: Zhu
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000963:Antimetabolites / Q000494:pharmacology; D001973:Bromodeoxyuridine / Q000378:metabolism; D002452:Cell Count / Q000379:methods; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D004195:Disease Models, Animal; D005473:Fluoxetine / Q000627:therapeutic use*; D020244:Infarction, Middle Cerebral Artery / Q000150:complications / Q000188:drug therapy; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D051379:Mice; D008810:Mice, Inbred C57BL; D055495:Neurogenesis / Q000187:drug effects*; D009474:Neurons / Q000187:drug effects* / Q000502:physiology; D011597:Psychomotor Performance / Q000187:drug effects; D011930:Reaction Time / Q000187:drug effects; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013028:Space Perception / Q000187:drug effects; D013550:Swimming; D013997:Time Factors; D015215:Zidovudine / Q000494:pharmacology
chemical_list: D000963:Antimetabolites; D001973:Bromodeoxyuridine; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors; D015215:Zidovudine